Guardant Health and Policlinico Gemelli Focus on Liquid Biopsy Testing
Significant Partnership for Liquid Biopsy Testing
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS ("Policlinico Gemelli") to establish a dedicated in-house liquid biopsy testing service in Italy. This service aims to provide comprehensive and timely diagnostics for cancer patients through advanced blood testing technologies.
Advancements in Precision Oncology
Through this collaboration, both organizations expect to improve the current diagnostic pathways available to oncologists and enhance patient outcomes. The innovative liquid biopsy methods will allow for better detection and monitoring of various cancers, significantly impacting Cancer Care in the region.
Why Liquid Biopsy Matters
- Non-invasive: liquid biopsies require only a blood sample.
- Cost-effective: it reduces the need for surgeries or invasive procedures.
- Real-time monitoring: allows for a better understanding of treatment responses.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.